OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer

Cancer Research

Volumn 76, Issue 13, 2016, Pages 3666-3670

  Svoronos, Alexander A ^a   Engelman, Donald M ^a   Slack, Frank J ^b  

^a YALE UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 122; MICRORNA 125B; MICRORNA 155; MICRORNA 214; MIRAVIRSEN; ONCOGENIC MICRORNA; PROTEIN BCL 2; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CHRONIC HEPATITIS C; CHRONIC LYMPHATIC LEUKEMIA; DENDRITIC CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC HETEROGENEITY; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; METASTASIS; NONHUMAN; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR VIRUS; ANIMAL; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; PATHOLOGY;

ANIMALS; CARCINOGENESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; NEOPLASMS; ONCOGENES;

EID: 84977553065     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-0359     Document Type: Review

References (33)

1. Medina PP, Nolde M, Slack FJ. Oncomi R addiction in an in vivo model of micro RNA-21-induced pre-B-cell lymphoma. Nature 2010;467:86-90.
2. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia 2012;26:2011-8.
3. Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 2013;6:6.
4. Tili E, Michaille JJ, Luo Z, Volinia S, Rassenti LZ, Kipps TJ, et al. The downregulation of miR-125b in chronic lymphocytic leukemias leads tometabolic adaptation of cells to a transformed state. Blood 2012;120:2631-8.
5. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488-96.
6. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, et al. Nanoparticle-based therapy in an in vivo micro RNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 2012;109: E1695-704.
7. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, et al. Micro RNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015;518:107-10.
8. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 2014;33:679-89.
9. Levati L, Pagani E, Romani S, Castiglia D, Piccinni E, Covaciu C, et al. Micro RNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res 2011;24:538-50.
10. Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, et al. micro RNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol Rep 2012;27:1960-6.
11. Qin W, Ren Q, Liu T, Huang Y, Wang J. Micro RNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett 2013;587: 1434-9.
12. Palma CA, Al Sheikha D, Lim TK, Bryant A, Vu TT, Jayaswal V, et al. Micro RNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia. Mol Cancer 2014;13:79.
13. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let- 7 micro RNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 2008;68:8535-40.
14. Saetrom P, Biesinger J, Li SM, Smith D, Thomas LF, Majzoub K, et al. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res 2009;69:7459-65.
15. Ramsingh G, Koboldt DC, Trissal M, Chiappinelli KB, Wylie T, Koul S, et al. Complete characterization of the micro RNA ome in a patient with acute myeloid leukemia. Blood 2010;116:5316-26.
16. Yu F, Jia X, Du F, Wang J, Wang Y, Ai W, et al. miR-155-deficient bone marrow promotes tumor metastasis. Mol Cancer Res 2013;11:923-36.
17. Zonari E, Pucci F, Saini M, Mazzieri R, Politi LS, Gentner B, et al. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood 2013;122:243-52.
18. Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 2012;72:1683-93.
19. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene 2014;33:2495-503.
20. Wu C, Jin B, Chen L, Zhuo D, Zhang Z, Gong K, et al. MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma. Cell Signal 2013;25:1212-21.
21. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011;20:104-18.
22. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, et al. Micro RNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov 2012;2:1100-8.
23. Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, et al. Micro RNA miR- 214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem 2012;287:34970-8.
24. Yin Y, Cai X, Chen X, Liang H, Zhang Y, Li J, et al. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res 2014;24:1164-80.
25. Xiang X, Zhuang X, Ju S, Zhang S, Jiang H, Mu J, et al. miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Oncogene 2011;30: 3440-53.
26. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, et al. Micro RNA-122, a tumor suppressor micro RNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009;49: 1571-82.
27. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting micro RNA. N Engl J Med 2013;368:1685-94.
28. Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak JJ, et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell 2015;160:1099-110.
29. Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci U S A 2014;111:4536-41.
30. Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF, Pogribny IP. Micro-RNA-mediated drug resistance in breast cancer. Clin Epigenetics 2011;2:171-85.
31. Kalinowski FC, Brown RA, Ganda C, Giles KM, Epis MR, Horsham J, et al. micro RNA-7: a tumor suppressor miRNA with therapeutic potential. Int J Biochem Cell Biol 2014;54:312-7.
32. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, et al. EGFR promotes lung tumorigenesis by activatingmiR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 2010;70:8822-31.
33. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of micro RNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010;127:1785-94.